Skip to Content

Kapvay Approval History

  • FDA approved: Yes (First approved September 28th, 2010)
  • Brand name: Kapvay
  • Generic name: clonidine hydrochloride
  • Dosage form: Extended-Release Tablets
  • Company: Shionogi Inc.
  • Treatment for: ADHD

Kapvay (clonidine hydrochloride) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

Development History and FDA Approval Process for Kapvay

Oct  4, 2010Approval Shionogi Announces FDA Approval of Kapvay - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.